CTNNB1 and endothelial dysfunction: PPARγ agonists can downregulate the Wnt/beta-catenin pathway, which is involved in inflammation, endothelial dysfunction, the proliferation of vascular smooth muscle cells, and vascular calcification, therefore PPARγ agonists might be therapeutic targets for the treatment of atherosclerosis [47].